{"filing":{"accession_number":"0001178913-26-004369","cik":"0001553846","ticker":"RDHL","company_name":"RedHill Biopharma Ltd.","form":"6-K","filing_date":"2026-09-01","report_date":"2026-09-01","primary_document":"zk2636058.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1553846/000117891326004369/zk2636058.htm"},"events":[{"id":30775,"run_id":28213,"accession_number":"0001178913-26-004369","anchor_item_number":"EX-99.1","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"This press release announces RedHill's acquisition of exclusive commercialization rights to Ferring's Rebyota® and Clenpiq® for a $12 million upfront payment plus tiered royalties and potential milestones. The transaction is explicitly described as \"transformational\" and represents a material strategic repositioning of RedHill's commercial GI business, funded by the previously announced $18 million Talicia divestiture. The acquisition of revenue-generating FDA-approved products materially expands RedHill's commercial portfolio and liquidity position, meeting the definition of material M\u0026A activity under Item 1.01/2.01.","company_name":"RedHill Biopharma Ltd.","ticker":"RDHL","filing_date":"2026-09-01","form":"6-K","submitted_at":null,"items":[{"id":33482,"accession_number":"0001178913-26-004369","item_number":"EX-99.1","item_title":"exhibit_99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"This press release announces RedHill's acquisition of exclusive commercialization rights to Ferring's Rebyota® and Clenpiq® for a $12 million upfront payment plus tiered royalties and potential milestones. The transaction is explicitly described as \"transformational\" and represents a material strategic repositioning of RedHill's commercial GI business, funded by the previously announced $18 million Talicia divestiture. The acquisition of revenue-generating FDA-approved products materially expands RedHill's commercial portfolio and liquidity position, meeting the definition of material M\u0026A activity under Item 1.01/2.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T11:10:45.312146+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33482,"accession_number":"0001178913-26-004369","item_number":"EX-99.1","item_title":"exhibit_99-1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"This press release announces RedHill's acquisition of exclusive commercialization rights to Ferring's Rebyota® and Clenpiq® for a $12 million upfront payment plus tiered royalties and potential milestones. The transaction is explicitly described as \"transformational\" and represents a material strategic repositioning of RedHill's commercial GI business, funded by the previously announced $18 million Talicia divestiture. The acquisition of revenue-generating FDA-approved products materially expands RedHill's commercial portfolio and liquidity position, meeting the definition of material M\u0026A activity under Item 1.01/2.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T11:10:45.312146+00:00","company_name":"RedHill Biopharma Ltd.","ticker":"RDHL","filing_date":"2026-09-01"}]}